title: Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage.
abstract: A shortage of donor organs and increasing dependence on marginal grafts with prolonged ischemic times have meant that new methods are needed to prevent postischemic damage. Herein is reported a new strategy aimed to protect donor kidney from complement-mediated postischemic damage and therefore increase the number of successful transplants. Rat donor kidneys were perfused with a membrane-localizing complement regulator derived from human complement receptor type 1 (APT070) and then subjected to prolonged periods of cold storage (at 4 degrees C). A relationship was found between the duration of cold ischemia and the extent of complement-mediated tubule damage and loss of graft function. After 16 h of cold storage, APT070-treated kidneys that were transplanted into syngeneic recipients showed a significant increase in the number of surviving grafts, compared with control-treated grafts (63.6 versus 26.3%). Surviving grafts also displayed less acute tubular injury and better preservation of renal function. These results not only enhance the understanding of the mechanism by which prolonged cold ischemia reduces immediate graft survival but also provide essential information about the effectiveness of membrane-localizing complement regulator with prolonged cold storage. This could lead to more effective strategies for improving the use of severely ischemic donor organs.
authors.affiliation: Department of Nephrology and Transplantation, 5th Floor, Thomas Guy House, Guy's Hospital, London SE1 9RT, UK.
authors.forename: Hetal
authors.initials: H
authors.lastname: Patel
authors.forename: Richard A G
authors.initials: RA
authors.lastname: Smith
authors.forename: Steven H
authors.initials: SH
authors.lastname: Sacks
authors.forename: Wuding
authors.initials: W
authors.lastname: Zhou
mesh_terms: D000818:Animals; D003080:Cold Temperature; D051056:Complement Inactivating Agents / Q000378:metabolism / Q000494:pharmacology*; D003169:Complement Inactivator Proteins / Q000378:metabolism; D006085:Graft Survival; D006801:Humans; D007511:Ischemia / Q000276:immunology / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000276:immunology / Q000293:injuries / Q000473:pathology; D016030:Kidney Transplantation; D008297:Male; D009926:Organ Preservation / Q000379:methods*; D051381:Rats; D017463:Receptors, Complement 3b / Q000378:metabolism; D013997:Time Factors
chemical_list: D051056:Complement Inactivating Agents; D003169:Complement Inactivator Proteins; D017463:Receptors, Complement 3b